SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
|
|
- Shauna Wilkins
- 5 years ago
- Views:
Transcription
1 SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018
2 Disclosures Participation in advisory boards: Astellas, Bayer, Janssen Research funding: Astra Zeneca, Bayer, Janssen Speaker fees: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer Travel, accomodation, expenses: Astellas, Bayer, Bristol-Myers,Janssen, Roche
3 Mitoxantrone Abiraterone Acetate Enzalutamide Orchiectomy Antiandrogens Zoledronic Acid Abiraterone Acetate Enzalutamide
4 Mitoxantone Metastatic disease Symptomatic (pain) ECOG 3 n=161 Mitoxantrone12 mg/m 2 q3w + Prednisone 5 mg/12h Placebo q3w + Prednisone 5 mg/12h Palliative response(29% vs 12%, p=0.01) Longer in Mitox. Arm (43 vs 18 weeks, p<.0001) No difference in Overall Survival Study endpoints: Primary: Pain improvement Secondary: PSA response, OS
5 Docetaxel TAX-327 Docetaxel75mg/m 2 q3w + Prednisone 5 mg/12h N=335 Metastatic No Chemo ECOG 2 n=1006 Docetaxel30 mg/m 2 1w + Prednisone 5 mg/12h N=334 Mitoxantrone12mg/m 2 q3w + Prednisone 5 mg/12h N=337 Study end points: Primary: OS Secondary: Pain reduction, QoL, 50% PSA decline, tumor response Improved OS (18.9m vs 16.5 m, p<0.001) 50% PSA decline (45% vs 32 %, p<0.001) Reduction in pain: 35 % vs 22 % (p=0.01) QoL:22% vs 13% (p=0.009) Tannock, NEJM, 2004
6 Docetaxel SWOG Metastatic disease ECOG 2 N=674 Estramustine 380 mg/8h D1-5 + Docetaxel60 mg/m 2 q21w + Prednisone 5 mg/12h N=338 Mitoxantrone12 mg/m 2 q3w + Prednisone 5 mg/12h N=336 Study end points: Primary: OS Secondary: PFS, 50% PSA decline, tumour response rate Petrylack, NEJM, 2004 Improved OS (17.5m vs 15.6 m, p=0.02) Improved PFS (6.3 m vs 3.2 m, p<0.001) 50% PSA decline: 50% vs 27%, p<0.001) Grade 3 or 4 Febrile Neutropenia (p=.01), nausea and vomiting (p=.001) and CV events (p=.001)
7 Cabazitaxel TROPIC Metastatic Symptomatic ECOG 2 Progression to docetaxel N=755 Cabazitaxel25 mg/m 2 q21w + Prednisone 5 mg/12h N=378 Mitoxantrone12 mg/m 2 q3w + Prednisone 5 mg/12h N=377 Study end points: Primary: OS Secondary: PFS, 50% PSA decline, PSA progression, objective tumour response rate, pain progression Improved OS (15.1m vs 12.7 m, p<.0001) Improved PFS (2.8 m vs 1.4 m, p<0.0002) 50% PSA decline: 39% vs 18%, p<0.001) No difference in pain response Febrile neutropenia: 8% vs 1% De Bono, 2010, Lancet
8 Efficacy NOV-22 (Mitoxantrone) TAX-327 (Docetaxel) SWOG (Docetaxel- Estr) TROPIC (Cabazitaxel) N 161 OS Exp arm OS Control Δ OS HR (CI95%) RECIST Response PSA Response months 16.5 months 2.4 months 0.76 ( ) months 15.6 months 1.9 months 0.80 ( ) month 12.7 months 2.4 months 0.70 ( ) 12% vs7 % (p=0.11) 17% vs11% (p=0.3) 14.4% vs4% (p<0.001) 45% vs32% (p<001) 50% vs27% (p<0.001) 39% vs18% (p<0.001) QoL Yes Yes No No
9 TOXICITY DOCETAXEL (TAX-327) CABAZITAXEL (TROPIC) Neutropenia(G3, G4): 32% vs 22% Febrile Neutropenia: 3% vs 2% Neutropenia(G3, G4): 82% vs 58% Febrile Neutropenia: 8% vs 1% Diarrhea(Any grade): 32% vs 10% Diarrhea(Any grade): 47% vs 11% (G3, G4): 6% vs <1% Peripheral neuropathy: 32% vs 10% Peripheral neuropathy: 14% vs 3% Others: Alopecia (65% vs 13%), Nail changes(30% vs 7%), stomatitis (20% vs8%), Edema (19% vs1%) Deaths due to causes other than disease progression 5% vs <1% Patients 65 years Neutropenia Diarrhea Monitoring GCSF
10 FIRSTANA Sartor, ASCO 2016
11 C20 and C25 not superior to D75 for OS Oudard et al, JCO, 2017
12 Oudard et al, JCO, 2017
13
14 Post-marketing requirement trial PROSELICA Hypothesis: C20 mantainsat least50% of theos benefitof C25 relative to mitroxantrone observed on the TROPIC study De Bono, ASCO 2016
15 C20 maintained 50% of the OS benefit of C25 Eisenberg, JCO, 2017
16 Secondary efficacy end-points favoured C25 Eisenberg, JCO, 2017
17 Less adverse events were observed with C20 Eisenberg, JCO, 2017
18 Combinations with docetaxel D Antonarakis, JCO, 2013
19 Radium Calcium mimetic - Accumulates in hydroxyapatite areas surrounding tumor lesions whereitbindsto áreas of increased turnover Apha particles induce doublestrand DNA breaks in adjacent tumour cells. Short penetration of alpha emitters(2-10 cells) = highly localizedtumourcellkillingand minimal damage to surrounding normal tissue Henriksen et al. Cancer Re 2002 Parker et al, Prostate Cancer Prost Dis, 2018
20 ALSYMPCA: Study Design PATIENTS (N=921) Confirmed symptomatic CRPC (EBRT or analgesia) 2 bone metastases Noknown visceral metastases Post-docetaxel, unfit for docetaxel, or refused docetaxel STRATIFICATION Total ALP: <220 U/L vs 220 U/L Bisphosphonate use: Yes vs No Prior docetaxel: Yes vs No R 2:1 Radium-223 (50 kbq/kg IV) 6 injections at 4-week intervals + best standard of care Placebo (saline) 6 injections at 4-week intervals + best standard of care ALSYMPCA was halted early after the positive efficacy results reported froma plannedinterim analysis of 809 patients with 314 deaths occurred. An updated analysis of efficacy and safety was performed from all 921 enrolled patients when 528 deaths had occurred. 20
21 Study Endpoints PRIMARY ENDPOINT Overall survival SECONDARY ENDPOINTS Time to total ALP progression Total ALP response Total ALP normalization Time to occurrence of first SSE ALSYMPCA had no radiographic review and so only symptomatic pathologic bone fractures were captured. Thus symptomatic skeletal event (SSE) was deemed a more clinically relevant term for this measurement. Time to PSA progression Other secondary efficacy endpoints Safety Quality of life ALP, alkaline phosphatase; PSA, prostate-specific antigen; SSE, symptomatic skeletal event. a.see slides ( Other Secondary Efficacy Endpoints ) for more details. b.defined as return of total ALP to within normal range at 12 weeks [confirmed by two consecutive measurements 2 weeks apart] in patients with total ALP values above upper limit of normal (ULN) at baseline. c. Defined as 25% increase from baseline and an absolute value increase 2 ng/ml at 12 weeks [in patients with no PSA decline from baseline] or 25% increase and an absolute value increase 2 ng/ml above nadir confirmed 3 weeks later, in patients with an initial decrease from baseline. SOURCE: Parker C, et al. N Engl J Med. 2013;369(3):
22 Radium-223 Significantly Improved Overall Survival Radium 223 Placebo Median OS (months) HR % CI P < Median OS Δ: 3.6 months Radium BSoC Placebo + BSoC Month Radium Placebo % reduction in risk of death (HR=0.70) for patients in the Radium-223 group
23 Radium-223 Significantly Improved Time to SSE Patients Without SSE (%) Median Δ: 5.8 months Radium BSoC Placebo + BSoC Radium 223 Placebo Median Time to SSE (months) HR % CI P < Month Radium Placebo
24 Secondary Efficacy Endpoints The significant improvement in all main secondary efficacy endpoints provided support for the benefit of radium-223 (+ BSoC) over placebo (+ BSoC). SECONDARY EFFICACY ENDPOINTS RADIUM-223 (n=614) PLACEBO (n=307) HAZARD RATIO (95% CI) P VALUE Median time to first SSE(months) ( ) <0.001 Median time to total ALP progression(months) ( ) <0.001 Median time to PSA progression(months) ( ) <0.001 Total ALP response ( 30% reduction), n (%) a 233/497 (47) 7/211 (3) <0.001 Total ALP normalization, n (%) a,b 109/321 (34) 2/140 (1) <0.001 ALP, alkaline phosphatase; BSoC, best standard of care; CI, confidence interval; ITT, intention-to-treat; PSA prostate-specific antigen; SSE, symptomatic skeletal event. a. Number of patients without missing values. b.in patients who had elevated total ALP at baseline. SOURCE: Parker C, et al. N Engl J Med. 2013;369(3):
25 Radium-223 Reduced the Risk of each individual SSE component Radium-223 is the only agent in advanced CRPC shown to decrease the risk of spinal cord compression in a phase 3 trial: 48% risk reduction 33%reduction in need of EBRT for bone pain INDIVIDUAL SSE COMPONENTS n a (%) RADIUM-223 (N=614) MEDIAN, b MONTHS n a (%) PLACEBO (N=307) MEDIAN, b MONTHS HR (95% CI) P VALUE c External beamradiation therapy 186 (30) (34) 17.5E 0.67 ( ) Symptomatic pathologic bone fracture 32 (5) NE 20 (7) NE 0.62 ( ) 0.10 Spinal cord compression 25 (4) NE 21 (7) NE 0.52 ( ) 0.03 Tumor-relatedorthopedic surgical intervention 12 (2) NE 7(2) NE 0.72 ( ) 0.48 CI, confidence interval. CRPC, castration-resistant prostate cancer. NE, not estimable. a. Number of patients. b. Median time to first event. 0 Favors 1 Favors 2 Radium-223 Placebo c. P values are for descriptive purpose only and not adjusted for multiplicity; the hazard ratio is the best interpretation of radium-223 effect. SOURCE:Sartor O, et al. Lancet Oncol. 2014;15(7):
26 ALP Response ALSYMPCA Efficacy: Biomarkers A significantly higher proportion of patients in the radium 223 group compared with the placebo group achieved total ALP response ( 30% reduction in total ALP; P <0.001) and normalization(p <0.001). PSA Response a Radium 223 Placebo P Value 30% Reduction in PSA blood levels at week 12 16% 6% < % Reductionin PSA blood levels sustained through end of treatment (4 weeks after last injection) 14% 4% <0.001
27 Radium-223 patients with a confirmed talpor LDH decline at week 12 had a significantly longer median OS versus radium-223 patients without talp or LDH decline Sartor et al, Ann Oncol 2017
28 Sartor, Abstract 2530 ASCO 2015
29 Parker et al, NEJM, 2013
30 Prior docetaxel use did not affect the incidence of grade 3 or 4 non-hematologic AEs PATIENTS WITH GRADE 3 or 4 AEs*, n (%) PREVIOUS DOCETAXEL USE RADIUM-223 (n=347) PLACEBO (n=171) NO PREVIOUS DOCETAXEL USE RADIUM-223 (n=253) PLACEBO (n=130) Diarrhea 2 (1) 4 (2) 7 (3) 1 (1) Nausea 8(2) 3 (2) 2 (1) 2 (2) Vomiting 9(3) 5 (3) 1 (<1) 2 (2) Constipation 3(1) 1 (1) 3 (1) 3 (2) Fatigue 16 (5) 10 (6) 8 (3) 8 (6) Peripheral edema 6 (2) 2 (2) 4 (2) 2 (2) Urinary tract infection 3 (1) 4 (3) 4 (2) 1 (1) Weight decreased 4 (1) 5 (0) 0 0 Anorexia 4 (1) 2 (1) 5 (2) 0 Bone pain 74 (21) 53 (31) 51 (21) 24 (19) Malignant neoplasm progression 5 (1) 4 (3) 8 (3) 1 (1)
31
32 Data review suggests that patients in the combination arm had an increased risk of fractures (28% vs 11%) and shortersurvival(median 31 vs 33 months) - EMA recommendation: - Symptomatic patients - notto use XOFIGO in combination - After 2 previous treatments for mcrpc - patients who cannot tolerate other treatments
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationRoberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Il Trattamento della Malattia CRPC metastatica Terapie Radiometaboliche Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM: Gestione ottimale del Paziente con Carcinoma della
More informationMÉTASTASES OSSEUSES ET RADIUM 223
MÉTASTASES OSSEUSES ET RADIUM 223 Marie-Laure Amram Service d oncologie Hôpitaux Universitaires de Genève Forome du 21.05.2015 Radium-22:3:mécanisme d action Mécanisme d action Mécanisme d action Radium-223
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationΛουκάς Κοντοβίνης, παθολόγος - ογκολόγος.
Λουκάς Κοντοβίνης, παθολόγος - ογκολόγος l.kontovinis@oncomedicare.com Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med 2004;350:1655-64 Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationAlpha-emitting Radionuclides: Ra-223
Alpha-emitting Radionuclides: Ra-223 prof. dr. K. Goffin Nuclear Medicine and Molecular Imaging Department of Imaging & Pathology UZ Leuven KU Leuven Belgium International Course on Theranostics and Molecular
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationDr. Tia Higano University of Washington Seattle, USA
AN UPDATE ON THE TREATMENT OF PATIENTS WITH mcrpc WITH RA-223 PLUS AAP Dr. Tia Higano University of Washington Seattle, USA AAP, Abiraterone Acetate and Prednisone/Prednisolone; mcrpc, metastatic Castration-Resistant
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationNAVIGATING THE mcrpc LANDSCAPE: EXPLORING KEY CLINICAL DECISION POINTS
NAVIGATING THE mcrpc LANDSCAPE: EXPLORING KEY CLINICAL DECISION POINTS Summary of presentations from the Bayer-supported satellite symposium, held at the European Association of Urology (EAU) Congress,
More informationCancer de la prostate: best of 2016
Cancer de la prostate: best of 2016 Dr Christophe Massard GR2016, 3 DEC 2016 Disclosure Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech,
More informationFUJI study: Follow-Up of Jevtana in real life
Pharmacologie médicale Bordeaux PharmacoEpi CIC Bordeaux CIC1401 FUJI study: Follow-Up of Jevtana in real life French retrospective and protective multicenter observational study describing the survival,
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationPublished in: European Urology. Document Version: Publisher's PDF, also known as Version of record
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial Parker, C., Finkelstein, S.
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationNavigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA Disclosures In compliance with accreditation, we require the following disclosures to the
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationRadiopharmaceuticals for treating CRPC patients with metastatic bone disease 2014/6/27
Radiopharmaceuticals for treating CRPC patients with metastatic bone disease 和信醫院黃玉儀 2014/6/27 Bone metastases in prostate cancer The most common site of metastasis in prostate cancer In >90% patients
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/28765 holds various files of this Leiden University dissertation. Author: Wissing, Michel Daniël Title: Improving therapy options for patients with metastatic
More informationManagement of chronic pre-existing or treatment-emergent adverse events of the other systemic therapies. Michael J. Morris, MD
Management of chronic pre-existing or treatment-emergent adverse events of the other systemic therapies Michael J. Morris, MD www.mskcc.org Disclosures Research funding (institutional contracts): Sanofi
More informationDecision follows a recommendation from Independent Data Monitoring Committee (IDMC)
News Release Intended for U.S. Media Phase III trial of radium Ra 223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate
More informationRadium-223 (Alpharadin)
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer OLIVER SARTOR, M.D. North American Principal Investigator, ALSYMPCA trial Laborde Professor
More informationSOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc
SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationAdvances in Chemotherapy for Castration Resistant Prostate Cancer
Advances in Chemotherapy for Castration Resistant Prostate Cancer Daniel P. Petrylak, MD Director, Genitourinary Oncology Co Director, Signal Transduction Program Yale Comprehensive Cancer Center Sequencing
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More informationEvolution of Chemotherapy for. Cancer
Evolution of Chemotherapy for Hormone Refractory Prostate t Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology Princess Margaret Hospital and University of Toronto In 1985, two
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationmcrpc in 2016 How to decide the optimal treatment? N. Mottet
mcrpc in 2016 How to decide the optimal treatment? N. Mottet Disclosures Conflict of interest Chairman EAU PCa guidelines..... Therefore I'm 100% biased Castrate-resistant prostate cancer (CRPC) Definition
More informationTherapeutic management of bone metastasis in prostate cancer: an update
Expert Review of Anticancer Therapy ISSN: 1473-7140 (Print) 1744-8328 (Online) Journal homepage: http://www.tandfonline.com/loi/iery20 Therapeutic management of bone metastasis in prostate cancer: an update
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationEconomic Evaluation of cabazitaxel (Jevtana ) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated
Economic Evaluation of cabazitaxel (Jevtana ) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. March 2012
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationRadium-223 in a Community Setting for Castration Resistant Prostate Cancer
Cancer and Clinical Oncology; Vol. 6, No. 1; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Radium-223 in a Community Setting for Castration Resistant Prostate
More informationUpdates on Use of Radiopharmaceu3cals in Clinical Trials August 22, 2017
Updates on Use of Radiopharmaceu3cals in Clinical Trials August 22, 2017 Evan Y. Yu, M.D. Professor of Medicine (Oncology) University of Washington Fred Hutchinson Cancer Research Center Discussion Topics
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationCurrent Chemotherapy for Castration Resistant Prostate Cancer
Current Chemotherapy for Castration Resistant Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine at Columbia University Medical Center/NY Presbyterian Hospital Disclosure Consultant: Sanofi Aventis,
More informationimproving outcomes and identifying predictors of survival in clinical practice
European Journal of Nuclear Medicine and Molecular Imaging (218) 45:2264 2273 https://doi.org/1.17/s259-18-483-3 ORIGINAL ARTICLE 223 Ra-Dichloride in castration-resistant metastatic prostate cancer: improving
More informationoriginal research Abstract Introduction
original research A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate Daniel Joseph Khalaf,
More information